Cancer – Breast – Page 3 – OncWonk – Dr Bier's Oncology Research Reviews

Risks of second primary cancers among 584,965 female and male breast cancer survivors in England: a 25-year retrospective cohort study

February 1, 2026

| Cancer - Breast, Cancers, Chemotherapy, Radiation Therapy

Comment: Although conventional treatments for breast cancer has made astounding improvements over the 35 years that I’ve been in the field, we have to acknowledge that along with it comes a long-term price paid by the patient’s systemic health. This study provides a definitive signal on the iatrogenic risks associated with the standard-of-care. The clinical […]

Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy

January 7, 2026

| No Comments

| Cancer - Breast, Radiation Therapy

Comment: The primary disconnect in this data is the dramatic, nearly five-fold reduction in local-regional recurrence that fails to translate into a statistically significant overall survival benefit for the general cohort. While a 10-year local recurrence rate of 11% compared to 22% is a clear victory for regional management, the P=.063 for overall survival reminds […]

Precautions for breast cancer-related lymphoedema: risk from air travel, ipsilateral arm blood pressure measurements, skin puncture, extreme temperatures, and cellulitis

January 1, 2026

| No Comments

| Cancer - Breast, Mastectomy-Lumpectomy

Comment: This synthesis serves as a robust rebuttal to the long-standing “precautions” that have dominated lymphedema education. The findings demonstrate that most traditional prohibitions—specifically air travel and blood pressure measurements—are effectively myths that lack Level 1 or 2 evidence. The core tension is between a historical focus with these external triggers and the clinical reality […]

Thyroid hormone enhances estrogen-mediated proliferation and cell cycle regulatory pathways in steroid receptor-positive breast Cancer

December 24, 2025

| No Comments

| Cancer - Breast, Medications - General Pharmaceuticals

Comment: This study provides the critical ‘why’ behind the findings from this same groups earlier study. In that article, we highlighted that exogenous thyroid hormone is associated with significantly shortened survival in SR+ breast cancer patients. Now, this research explains elucidates the underlying mechanism: thyroid hormone essentially ‘hijacks’ the estrogen receptor, driving proliferation and rendering […]

Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers

December 24, 2025

| No Comments

| Cancer - Breast, Medications - General Pharmaceuticals

Comment: This paper serves as a major wake-up call regarding the risks of thyroid replacement in SR+ breast cancer, which compromises about 80% of cases. The mechanistic finding—that thyroid hormone can reverse Tamoxifen’s action from antagonist to agonist—is a critical piece of the puzzle explaining treatment failure. Furthermore, the observation that Aromatase Inhibitors also showed […]

Post-diagnosis supplement use and breast cancer prognosis in the After Breast Cancer Pooling Project

December 20, 2025

| No Comments

| Cancer - Breast, Supplements

Comment: Cancer survivors are still frequently told that they should avoid antioxidants due to the wholly theoretical risk that they might ‘rescue’ residual cancer cells. This large-scale analysis effectively dismantles that dogma. Instead of harm, we see a clear survival advantage—a 16% reduction in total mortality for those using antioxidants post-treatment. Whether it is the […]

Antioxidant supplementation and breast cancer prognosis in postmenopausal women undergoing chemotherapy and radiation therapy

December 20, 2025

| No Comments

| Cancer - Breast, Chemotherapy, HRT - Hormone Replacement Therapy, Supplements

Comment: While the headline of this study suggests a clear danger, the methodology reveals significant issues which makes the results difficult to trust. They ‘lump’ biologically distinct agents—grouping trace minerals like selenium with high-dose Vitamin C—which renders the ‘antioxidant’ variable clinically meaningless. This is the same mistake done in this trial, which is really a […]

NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup

December 17, 2025

| No Comments

| Cancer - Breast, Medications - General Pharmaceuticals

Comment: This study is not the only one showing NSAIDs (vs tylenol) for pain management around surgery has a potential upside. However what this ones suggests is that ketorolac specifically may be a better option than other NSAIDS. that a standard perioperative analgesic acts as a potent anti-cancer agent by ‘abrogating’ the specific inflammatory signal […]

Breast cancer patients enrolled in the Swiss mammography screening program “donna” demonstrate prolonged survival

December 13, 2025

| No Comments

| Cancer - Breast, Mammography - Mammogram

Comment: While this data from the ‘donna’ program shows a statistically significant survival advantage for screened patients, we can’t conflate ‘survival’ with ‘reduced mortality.’ The study design focuses on women already diagnosed with breast cancer, which inherently makes the results susceptible to lead-time bias—where earlier detection creates an illusion of longer survival without necessarily changing […]

A systematic review of elastography, electrical impedance scanning, and digital infrared thermography for breast cancer screening and diagnosis

December 13, 2025

| No Comments

| Cancer - Breast, Mammography - Mammogram

Comment: While the appeal of ‘radiation-free’ screening is undeniable, the evidence presented in this review should give anyone recommending thermography pause. The extreme variability in diagnostic accuracy—with sensitivity swinging wildly from 25% to 97%—makes these tools clinically unpredictable. Crucially, the complete absence of data on asymptomatic women means we are effectively flying blind if we […]